COAG earnings
Hemab Therapeutics Holdings Inc. (COAG) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model; data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026 Announced first clinical data for sutacimig in Factor VII deficiency (FVIID), showing shortening of prothrombin time by more than 50% in both participants and ~5x accumulation of endogenous FVII(a) in the participant with PK/PD data, after a single dose; updated Phase 2b data to be presented at ASH in December 2026 Initiated SOLARA, a p
- Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that it will host a conference call on Tuesday, November 10, at 8:00 a.m. ET to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026. Listeners can register for the webcast on the investors page of the company’s website (https://ir.hemab.com/) or directly through this link. Analysts wishing to participate in the question and answer session should use this